Asembia AXS26: Closing the Gap Between Prescription Fill and Patient Use

Patient adherence is a key factor linking clinical outcomes to performance across specialty pharma. In his interview with Pharmaceutical Commerce at Asembia AXS26, Kieran Daly, general manager and co-founder of HealthBeacon, explained that adherence supports positive patient outcomes, which in turn underpin broader value across the system. He noted that when patients stay on schedule with their treatment, they are more likely to build consistent habits and remain on therapy, which can lead to additional prescription fills over time.

Daly also pointed to a gap in how adherence is typically measured. While stakeholders can track shipments and refills, these methods do not show what happens once the medication reaches the patient’s home. He described this as a missing link, where patients are managing treatment on their own without clear visibility. To address this, Daly pointed to connected, in-home tools that can track when injections are administered by capturing timestamped data, giving providers greater visibility into whether patients are staying on track with their regimen.

This type of data is becoming more relevant as value and outcomes receive greater focus. Daly noted that stakeholders are increasingly asking not just whether a prescription was filled, but whether the patient is actually taking the medication. He added that in cases where patients are not achieving expected outcomes, non-adherence is often a contributing factor, making proof of use an important component of evaluating treatment effectiveness.